A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients WithTriple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy